These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38722541)

  • 1. PharmacoEconomics Supplement : Advancing measurement of children's health-related quality of life - evidence from the QUOKKA (QUality OF Life in Kids: Key evidence to strengthen decisions in Australia) research program.
    Pharmacoeconomics; 2024 Jun; 42(Suppl 1):1. PubMed ID: 38722541
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging role of pharmacoeconomics in the research and development decision-making process.
    DiMasi JA; Caglarcan E; Wood-Armany M
    Pharmacoeconomics; 2001; 19(7):753-66. PubMed ID: 11548911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recording of quality of life in dermatological studies. Guidelines of the Subcommission "Pharmacoeconomics and Quality of Life"].
    Augustin M;
    Hautarzt; 2001 Aug; 52(8):697-700. PubMed ID: 11544939
    [No Abstract]   [Full Text] [Related]  

  • 4. The Children's Health Insurance Program Reauthorization Act quality measures initiatives: moving forward to improve measurement, care, and child and adolescent outcomes.
    Dougherty D; Schiff J; Mangione-Smith R
    Acad Pediatr; 2011; 11(3 Suppl):S1-S10. PubMed ID: 21570012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to implementing pharmacoeconomics: interview study.
    Alefan Q; Hamdouni E; Alhamad H; Mukattash T; Rascati K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):93-104. PubMed ID: 32394752
    [No Abstract]   [Full Text] [Related]  

  • 6. PharmacoEconomics Supplement : Advancing methods to measure and reward healthcare innovation: results from the valuing innovation project.
    Pharmacoeconomics; 2024 Jul; 42(Suppl 2):181. PubMed ID: 38878151
    [No Abstract]   [Full Text] [Related]  

  • 7. The relevance of international studies to informed pharmacoeconomics and health policy decisions.
    Lyles A
    Clin Ther; 2010 Jan; 32(1):106-7. PubMed ID: 20171416
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacoeconomics and policy decisions: the Australian health care system.
    Henry D; Lopert R
    Clin Ther; 1999 May; 21(5):909-15. PubMed ID: 10397384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin.
    Lopert R; Lang DL; Hill SR
    J Clin Pharm Ther; 2003 Jun; 28(3):243-9. PubMed ID: 12795784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex intervention to promote human papillomavirus (HPV) vaccine uptake in school settings: A cluster-randomized trial.
    Davies C; Marshall HS; Brotherton JML; McCaffery K; Kang M; Macartney K; Garland SM; Kaldor J; Zimet G; Skinner SR;
    Prev Med; 2023 Jul; 172():107542. PubMed ID: 37172767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.
    Thwaites R; Townsend RJ
    Pharmacoeconomics; 1998 Feb; 13(2):175-80. PubMed ID: 10178645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries.
    Eljilany I; El-Dahiyat F; Curley LE; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):403-414. PubMed ID: 29779401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the effectiveness of Australian early childhood education and care experiences: study protocol.
    Tayler C; Cloney D; Adams R; Ishimine K; Thorpe K; Nguyen TK
    BMC Public Health; 2016 Apr; 16():352. PubMed ID: 27098954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the quality of the websites of pharmacoeconomics and health economics centers through a validated questionnaire].
    Domínguez-Castro A; Iñesta-García A
    Gac Sanit; 2004; 18(4):295-304. PubMed ID: 15324640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomics. I].
    Kolár J
    Ceska Slov Farm; 1997 Feb; 46(1):9-13. PubMed ID: 9221090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital drug and therapeutics committees in Australia: is there a role for economic evaluation at the institutional level?
    Gallego G
    Int J Clin Pharm; 2011 Dec; 33(6):895-7. PubMed ID: 21922271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics: NICE's approach to decision-making.
    Rawlins M; Barnett D; Stevens A
    Br J Clin Pharmacol; 2010 Sep; 70(3):346-9. PubMed ID: 20716233
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics of biotechnology drugs (2).
    Hui JW; Yee GC
    J Am Pharm Assoc (Wash); 1998; 38(2):231-3. PubMed ID: 9654852
    [No Abstract]   [Full Text] [Related]  

  • 20. Current principles and application of pharmacoeconomics.
    Malek M
    Pharmacoeconomics; 1996; 9 Suppl 1():1-8. PubMed ID: 10160111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.